PolyOne Corporation received the Frost & Sullivan 2009 North American Plastics in Medical Tubing & Catheters Product Line Strategy of the Year Award. The award highlights PolyOne's continuous innovations that provide sustainable solutions for the medical industry.
Walter Ripple, general manager, PolyOne's GLS Thermoplastic Elastomers (TPEs), says, "Our R&D efforts include creating new compounds that address environmental concerns such as phthalates, while continuing to offer excellent performance and aesthetics. Our Versaflex HC family of TPEs, made without phthalates or halogens, helps our customers meet performance, regulatory and environmental objectives."
Frost & Sullivan, a global research and consulting firm, presents the Product Line Strategy Award to companies that most effectively address their customer's diverse needs with regard to price, performance and benefits. PolyOne was presented with this award in recognition of its outstanding leadership in the plastics industry and exceptional medical grade TPE technologies for drug and fluid delivery systems.
The growth of TPEs in the medical tubing market stems from the materials' effectiveness as a replacement for traditional polymers. GLS Versaflex HC MT medical grade TPE offers customers a non-phthalate, halogen-free option designed to address this growing trend, providing an alternative for a number of medical tubing applications such as IV catheters, peristaltic pumps, and surgical drainage tubing.
Latest from Today's Medical Developments
- NextDent 300 MultiJet printer delivers a “Coming of Age for Digital Dentistry” at Evolution Dental Solutions
- Get recognized for bringing manufacturing back to North America
- Adaptive Coolant Flow improves energy efficiency
- VOLTAS opens coworking space for medical device manufacturers
- MEMS accelerometer for medical implants, wearables
- The compact, complex capabilities of photochemical etching
- Moticont introduces compact, linear voice coil motor
- Manufacturing technology orders reach record high in December 2025
